Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets
DOI 10.1007/s00125-003-1295-1
Lau T, Carlsson PO, Leung PS (2004) Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 47:240-248 (Pubitemid 38315360)
Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes
DOI 10.2337/diabetes.55.02.06.db05-1022
Chu KY, Lau T, Carlsson PO, Leung PS (2006) Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 55:367-374 (Pubitemid 43343265)
Angiotensin II type 1 receptor antagonism mediates uncoupling protein 2-driven oxidative stress and ameliorates pancreatic islet beta-cell function in young type 2 diabetic mice
DOI 10.1089/ars.2007.1590
Chu KY, Leung PS (2007) Angiotensin II type 1 receptor antagonism mediates uncoupling protein 2-driven oxidative stress and ameliorates pancreatic islet beta-cell function in young type 2 diabetic mice. Antioxid Redox Signal 9:869-878 (Pubitemid 46919590)
Combination of the dipeptidyl peptidase IV inhibitor LAF237 [S-1-[3-hydroxy-1-adamantylammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-1-oxopentyl-N-[[2′-1 H-tetrazol-5-yl-[1,1′-biphenyl]-4-yl]methyl]-L-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes
Cheng Q, Law PK, de Gasparo M, Leung PS (2008) Combination of the dipeptidyl peptidase IV inhibitor LAF237 [S-1-[3-hydroxy-1-adamantylammo]acetyl- 2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-1-oxopentyl-N-[[2′-1 H-tetrazol-5-yl-[1,1′-biphenyl]-4-yl] methyl]-L-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetesJ Pharmacol Exp Ther 327:683-691
3 is a negative endocrine regulator of the renin-angiotensin system
DOI 10.1172/JCI200215219
Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP (2002) 1, 25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229-238 (Pubitemid 34787360)
Angiotensin II exerts glucose-dependent effects on Kv currents in mouse pancreatic beta-cells via angiotensin II type 2 receptors
Chu KY, Cheng Q, Chen C et al (2010) Angiotensin II exerts glucose-dependent effects on Kv currents in mouse pancreatic beta-cells via angiotensin II type 2 receptors. Am J Physiol Cell Physiol 298:C313-C323
Involvement of the vitamin D receptor in energy metabolism: Regulation of uncoupling proteins
Wong KE, Szeto FL, Zhang W et al (2009) Involvement of the vitamin D receptor in energy metabolism: regulation of uncoupling proteins. Am J Physiol Endocrinol Metab 296:E820-E828
Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance: The Medical Research Council Ely Prospective Study 1990-2000
Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ (2008) Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000. Diabetes 57:2619-2625